![banner](/uploads/tarihce_53e2c81334.png?width=3840&quality=100)
Basın Bülteni
Press Room
![First in Europe Turgut Pharmaceuticals](/uploads/avrupa_birincisi_turgut_ilaclari_189c289dde.png?width=828&quality=100)
First in Europe Turgut Pharmaceuticals
The SR4SB Project, run by Turgut İlaçları A.Ş., was selected as the European First in the 2022 EURIPIDES² Innovation Awards.
![That First Day's Vision, Today's Righteous Pride](/uploads/o_ilk_gunku_vizyon_bugunun_hakli_gururu_a839b353e3.png?width=828&quality=100)
That First Day's Vision, Today's Righteous Pride
The Biopharmaceutical facility established by Turgut Pharmaceuticals in Gebze, which developed and produced Turkey's first end-to-end Biosimilar Monoclonal Antibody and completed its Phase 1 study, received the TITCK Approved GMP Certificate.
![Turgut Pharmaceuticals, a pioneer in its sector](/uploads/sektorunde_oncu_yine_turgut_ilaclari_a679a96c11.png?width=828&quality=100)
Turgut Pharmaceuticals, a pioneer in its sector
Turgut Pharmaceuticals continues to draw attention with its success in the health sector and its pioneering position against its competitors.